SR9011
Aliases: SR-9011
Last verified: 2026-09-23
The short version
A second REV-ERB agonist (α/β) from the same series — similar to SR9009 with a slightly different profile; fully preclinical. Key fact: No controlled human trials exist. Everything known about SR9011 in humans comes from indirect sources and self-reports. Status: preclinical. Not approved; WADA-banned (S4).
Identity & type
- Molecular type
- mali molekul
- Origin
- A second REV-ERB agonist (α/β) from the same series — similar to SR9009 with a slightly different profile; fully preclinical.
Mechanism of action
REV-ERBα/β agonism → metabolic reprogramming.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for SR9011. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
No human regimens. Similar to SR9009, even rarer experiences; inconsistent effects.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Similar to SR9009, even rarer experiences; inconsistent effects.
Protocol — official vs community
Official / label
No approved product. Successor to SR9009 with improved properties — still preclinical.
Duration: —
Exists because SR9009's PK failed; inherits the same evidence gap.
Community (anecdotal)
10–20 mg oral daily.
- Cycle:
- 8 weeks.
- Break:
- 4 weeks.
Slightly better pharmacokinetics, identical evidentiary status.
Human evidence
No controlled human trials exist. Everything known about SR9011 in humans comes from indirect sources and self-reports.
Preclinical evidence
Preclinical.
Known risks
- Unknown in humans.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.